2016至2020年日本吴市抗骨吸收药物相关颌骨坏死发病率及趋势
该研究基于日本吴市2015年建立的颌骨坏死登记系统与理赔数据库,纳入2016至2021年98例颌骨坏死患者,按抗骨吸收药物剂量分层估算2016至2020年发病率及趋势。结果显示,低剂量用药的骨质疏松患者发病率为每10万人132.5例,高剂量用药的癌症患者为每10万人2305.8例,无用药人群为每10万人5.1例,发病率比分别为23.6和420.6。
要点
- 低剂量抗骨吸收药物的骨质疏松患者颌骨坏死发病率比为23.6(p<0.001,95%CI 13.3-41.8)。
- 高剂量抗骨吸收药物的癌症患者颌骨坏死发病率比为420.6(p<0.001,95%CI 220.8-801.4)。
- 2016至2020年药物相关颌骨坏死总体发病率上升,高剂量组发病率下降但无统计学显著性。
核心结论
- 研究展示了日本吴市开展多专业协作研究后5年间按抗骨吸收药物剂量分层的颌骨坏死发病率及趋势。
- 针对颌骨坏死早期发现与预防的协作研究将继续进行。
研究设计与样本
- 基于2015年建立的颌骨坏死登记系统,纳入2016至2021年98例符合标准的颌骨坏死患者。
- 药物相关颌骨坏死依据美国口腔颌面外科医师协会标准诊断。
- 从理赔数据库获取使用与未使用抗骨吸收药物者的年度人数;癌症患者用药定义为高剂量,骨质疏松患者用药定义为低剂量。
主要发现
- 高剂量药物相关颌骨坏死年发病率为每10万人2305.8例,低剂量为每10万人132.5例,无抗骨吸收药物人群颌骨坏死发病率为每10万人5.1例。
- 使用低剂量抗骨吸收药物的骨质疏松患者相比未用药人群的发病率为23.6(p<0.001,95%CI 13.3-41.8)。
- 使用高剂量抗骨吸收药物的癌症患者相比未用药人群的发病率比为420.6(p<0.001,95%CI 220.8-801.4)。
- 2016至2020年药物相关颌骨坏死发病率上升,但高剂量药物相关颌骨坏死的发病率下降,尽管无统计学显著性。
关键数值与推荐
- 药物相关颌骨坏死的诊断依据美国口腔颌面外科医师协会标准。
- 高剂量与低剂量抗骨吸收药物分别定义为癌症患者与骨质疏松患者所用药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We investigated the incidence/trend of osteonecrosis of the jaw by antiresorptive agent dose over a 5-year period in Kure city, Japan. The incidence was 24 times higher among osteoporosis patients with low-dose agents and 421 times higher among cancer patients with high-dose agents than in the population without agents. PURPOSE: We launched the registry system of osteonecrosis of the jaw (ONJ) cases in 2015 to investigate the trend in ONJ incidence. The purpose of our study was to estimate the ONJ incidence among patients with antiresorptive agent use by dosage and people without antiresorptive agent use in Kure and its trend from 2016 to 2020. METHODS: From 2016 to 2021, 98 eligible ONJ patients were enrolled. Medication-related ONJ (MRONJ) was diagnosed based on the American Association of Oral and Maxillofacial Surgeons criteria. The annual number of those with and without antiresorptive agents was obtained from the claims database. Antiresorptive agents used for cancer and osteoporosis patients were defined as high- and low-dose medications, respectively. RESULTS: The annual incidence of high-dose MRONJ was 2305.8 per 100,000 and that of low-dose MRONJ was 132.5 per 100,000, while the ONJ incidence among people without antiresorptive agents was 5.1 per 100,000. The incidence ratio was 23.6 (p < 0.001, 95% confidence interval (CI) 13.3-41.8) among osteoporosis patients who used low-dose antiresorptive agents and 420.6 (p < 0.001, 95% CI 220.8-801.4) among cancer patients who used high-dose agents compared with people who did not use these agents. MRONJ incidence increased from 2016 to 2020, but the incidence of high-dose MRONJ decreased, although this was nonsignificant. CONCLUSION: We demonstrated the incidence and trend of ONJ by antiresorptive agent dose over a 5-year period in Kure after launching the multiprofession study. This collaborative study for the early detection and prevention of ONJ will continue.
引用
- Kunihara T, Tohmori H, Tsukamoto M, et al. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos Int. 2023. PMID: 37002373. doi:10.1007/s00198-023-06732-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。